191 related articles for article (PubMed ID: 34129075)
1. Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma.
Schultz CR; Swanson MA; Dowling TC; Bachmann AS
Cancer Chemother Pharmacol; 2021 Oct; 88(4):607-617. PubMed ID: 34129075
[TBL] [Abstract][Full Text] [Related]
2. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.
Samal K; Zhao P; Kendzicky A; Yco LP; McClung H; Gerner E; Burns M; Bachmann AS; Sholler G
Int J Cancer; 2013 Sep; 133(6):1323-33. PubMed ID: 23457004
[TBL] [Abstract][Full Text] [Related]
3. A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
Saulnier Sholler GL; Gerner EW; Bergendahl G; MacArthur RB; VanderWerff A; Ashikaga T; Bond JP; Ferguson W; Roberts W; Wada RK; Eslin D; Kraveka JM; Kaplan J; Mitchell D; Parikh NS; Neville K; Sender L; Higgins T; Kawakita M; Hiramatsu K; Moriya SS; Bachmann AS
PLoS One; 2015; 10(5):e0127246. PubMed ID: 26018967
[TBL] [Abstract][Full Text] [Related]
4. Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma.
Koomoa DL; Yco LP; Borsics T; Wallick CJ; Bachmann AS
Cancer Res; 2008 Dec; 68(23):9825-31. PubMed ID: 19047162
[TBL] [Abstract][Full Text] [Related]
5. DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.
Koomoa DL; Geerts D; Lange I; Koster J; Pegg AE; Feith DJ; Bachmann AS
Int J Oncol; 2013 Apr; 42(4):1219-28. PubMed ID: 23440295
[TBL] [Abstract][Full Text] [Related]
6. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells.
Wallick CJ; Gamper I; Thorne M; Feith DJ; Takasaki KY; Wilson SM; Seki JA; Pegg AE; Byus CV; Bachmann AS
Oncogene; 2005 Aug; 24(36):5606-18. PubMed ID: 16007177
[TBL] [Abstract][Full Text] [Related]
7. Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma.
Lozier AM; Rich ME; Grawe AP; Peck AS; Zhao P; Chang AT; Bond JP; Sholler GS
Oncotarget; 2015 Jan; 6(1):196-206. PubMed ID: 25415050
[TBL] [Abstract][Full Text] [Related]
8. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.
Rounbehler RJ; Li W; Hall MA; Yang C; Fallahi M; Cleveland JL
Cancer Res; 2009 Jan; 69(2):547-53. PubMed ID: 19147568
[TBL] [Abstract][Full Text] [Related]
9. Synergistic drug combination GC7/DFMO suppresses hypusine/spermidine-dependent eIF5A activation and induces apoptotic cell death in neuroblastoma.
Schultz CR; Geerts D; Mooney M; El-Khawaja R; Koster J; Bachmann AS
Biochem J; 2018 Jan; 475(2):531-545. PubMed ID: 29295892
[TBL] [Abstract][Full Text] [Related]
10. Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine.
Merali S; Clarkson AB
Antimicrob Agents Chemother; 1996 Apr; 40(4):973-8. PubMed ID: 8849262
[TBL] [Abstract][Full Text] [Related]
11. Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling.
Mohammed A; Janakiram NB; Madka V; Ritchie RL; Brewer M; Biddick L; Patlolla JM; Sadeghi M; Lightfoot S; Steele VE; Rao CV
Cancer Prev Res (Phila); 2014 Dec; 7(12):1198-209. PubMed ID: 25248858
[TBL] [Abstract][Full Text] [Related]
12. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.
Hogarty MD; Norris MD; Davis K; Liu X; Evageliou NF; Hayes CS; Pawel B; Guo R; Zhao H; Sekyere E; Keating J; Thomas W; Cheng NC; Murray J; Smith J; Sutton R; Venn N; London WB; Buxton A; Gilmour SK; Marshall GM; Haber M
Cancer Res; 2008 Dec; 68(23):9735-45. PubMed ID: 19047152
[TBL] [Abstract][Full Text] [Related]
13. Targeting Ornithine Decarboxylase by α-Difluoromethylornithine Inhibits Tumor Growth by Impairing Myeloid-Derived Suppressor Cells.
Ye C; Geng Z; Dominguez D; Chen S; Fan J; Qin L; Long A; Zhang Y; Kuzel TM; Zhang B
J Immunol; 2016 Jan; 196(2):915-23. PubMed ID: 26663722
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of polyamine biosynthesis decrease the expression of the metalloproteases meprin alpha and MMP-7 in hormone-independent human breast cancer cells.
Matters GL; Manni A; Bond JS
Clin Exp Metastasis; 2005; 22(4):331-9. PubMed ID: 16170669
[TBL] [Abstract][Full Text] [Related]
15. Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.
Evageliou NF; Haber M; Vu A; Laetsch TW; Murray J; Gamble LD; Cheng NC; Liu K; Reese M; Corrigan KA; Ziegler DS; Webber H; Hayes CS; Pawel B; Marshall GM; Zhao H; Gilmour SK; Norris MD; Hogarty MD
Clin Cancer Res; 2016 Sep; 22(17):4391-404. PubMed ID: 27012811
[TBL] [Abstract][Full Text] [Related]
16. Anti-GD2 induced allodynia in rats can be reduced by pretreatment with DFMO.
Diccianni MB; Kempińska K; Gangoti JA; Yu AL; Sorkin LS
PLoS One; 2020; 15(7):e0236115. PubMed ID: 32697811
[TBL] [Abstract][Full Text] [Related]
17. Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine Resistant Pancreatic Cancer.
Gitto SB; Pandey V; Oyer JL; Copik AJ; Hogan FC; Phanstiel O; Altomare DA
Mol Pharm; 2018 Feb; 15(2):369-376. PubMed ID: 29299930
[TBL] [Abstract][Full Text] [Related]
18. DFMO inhibition of neuroblastoma tumorigenesis.
Gandra D; Mulama DH; Foureau DM; McKinney KQ; Kim E; Smith K; Haw J; Nagulapally A; Saulnier Sholler GL
Cancer Med; 2024 May; 13(9):e7207. PubMed ID: 38686627
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of lupus nephritis in MRL-lpr/lpr mice by inhibiting ornithine decarboxylase.
Gunnia UB; Amenta PS; Seibold JR; Thomas TJ
Kidney Int; 1991 May; 39(5):882-90. PubMed ID: 2067204
[TBL] [Abstract][Full Text] [Related]
20. Effects of alpha-difluoromethylornithine and recombinant interferon-alpha 2 on the growth of a human renal cell adenocarcinoma xenograft in nude mice.
Heston WD; Fleischmann J; Tackett RE; Ratliff TL
Cancer Res; 1984 Aug; 44(8):3220-5. PubMed ID: 6430546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
